相关实验视频

Updated: Feb 4, 2026

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

准SH3GL1用于乳腺癌的预后和免疫反应

Si Si¹, Hong Yu², Hao Zhang³

¹Department of Obstetrics, The First Hospital of China Medical University, Shenyang, 110001, China.

Journal of pharmaceutical analysis

|February 3, 2026

概括

与cuproptosis相关的基因SH3GL1在乳腺癌 (BRCA) 中过度表达,与预后不佳和免疫疗法反应降低相关. 向SH3GL1可能为BRCA患者提供新的治疗策略.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
遗传学遗传学是一个

背景情况:

与cuproptosis相关的基因 (CRG) SH3GL1在癌症进展中发挥着作用.
了解SH3GL1在乳腺癌 (BRCA) 中的功能对于开发新疗法至关重要.

研究的目的:

研究SH3GL1在BRCA进展和免疫调节中的作用.
评估SH3GL1作为预后生物标志物和BRCA中的潜在治疗标.

主要方法:

基因表达概况和公共数据集的元分析.
单细胞RNA测序 (scRNA-seq) 用于分析细胞表达和相互作用.
功能实验评估SH3GL1对细胞迁移和药物敏感性的影响.
TIDE (瘤免疫功能障碍和排除) 评分用于预测免疫治疗反应.

主要成果:

在BRCA组织中,SH3GL1显著过度表达,并与患者的预后不佳有关.
scRNA-seq揭示了SH3GL1在上皮细胞中的表达以及与T细胞和单细胞的相互作用.
SH3GL1促进免疫细胞迁移,影响药物敏感性,并与降低免疫疗法反应有关.
高SH3GL1表达与高风险BRCA中的复杂免疫微环境相关.

结论:

在BRCA中,SH3GL1充当预后生物标志物.
SH3GL1影响瘤的免疫微环境和药物敏感性.
向SH3GL1为个性化BRCA治疗提供了一个潜在的治疗策略.

关键词:

乳腺癌是什么? 乳腺癌是什么这种疾病叫做cuproptosis.免疫微环境是一个微环境.预测生物标志物预测生物标志物这就是SH3GL1的原因.

更多相关视频

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

相关概念视频

Humoral Immune Responses

Humoral Immune Responses

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Cells of the Adaptive Immune Response

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...

Immune Response Against Viral Pathogens

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

Cells of the Innate Immune Response

Cells of the Innate Immune Response

The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...